MenoCheck® – FDA cleared as an aid in the determination of menopausal status

November 2, 2018

MenoCheck® – FDA cleared as an aid in the determination of menopausal status

Ansh Labs Earns De Novo FDA Clearance for picoAMH ELISA, trademarked MenoCheck®


Thursday, October 25, 2018 (Webster, TX) – Ansh Labs announced today that it received clearance from U.S. Food and Drug Administration (FDA) for the de novo application of its Anti-Müllerian (AMH) assay kit, picoAMH ELISA, which is sold under the trademark MenoCheck®.


The assay kit is intended for use as an aid in the determination of menopausal status in women between 42 and 62 years of age. This is the first approved AMH test with the sensitivity to quantify declining AMH concentrations in women who are entering their menopausal transition.


Blood levels of AMH have been shown to be highly correlated with the number of primordial follicles in an ovary (i.e., the true ovarian reserve).  The number of follicles declines with age, and the natural cause of menopause is the absence of these follicles.  MenoCheck was developed to achieve extremely sensitive measurements of AMH providing a significant new parameter to aid physicians in determining the status of women during the menopausal transition.


Presently, menopause is determined retrospectively, since it is clinically defined by the absence of a menstrual cycle (i.e., 12 months of amenorrhea). The duration and intensity of physiological changes or vasomotor symptoms is highly variable among women during the menopausal transition. Determining where a woman is in this process is clinically important.


A sensitive AMH test result will help physicians to understand the symptoms the patient is experiencing and to select an appropriate treatment to ameliorate those symptoms and prevent complications associated with the onset of menopause. For example, determining the onset of menopause at an early age may indicate to the physician the need to investigate the potential for accelerated bone loss leading to osteoporosis. This is a significant health issue in post-menopausal women.


Dr. Courtney Lias, Director of Chemistry and Toxicology Devices at the FDA, writes, “Diagnostic results about a woman’s menopausal status may prompt discussions about preventative care for women experiencing menopausal symptoms. This test, when used in conjunction with other clinical assessments and laboratory findings, can help inform discussions about preventative care, such as ways to help prevent loss in bone mineral density or to address cardiovascular disease, both of which are known to increase after menopause.”


The new picoAMH ELISA device uses well-established chemical principles, methodology, and components for the quantitative determination of AMH in human serum. The specificity of the antibodies, recombinant human AMH used for calibrators, and the enhanced sensitivity of the picoAMH ELISA are advantageous for the intended use of the device as an aid in the determination of menopausal status.


Ansh Labs was founded in 2011. The company is headquartered in Webster, TX.  The experienced management and development teams are the leading developers and manufacturers of reproductive endocrine immunoassay test kits that are used around the world. The company is narrowly focused on women’s health in reproduction, pregnancy and cardiometabolic health. Ansh Labs develops biomarkers intended to advance target discovery, therapeutic development, biomedical research, and clinical diagnostics.  The company serves life science researchers, physician researchers, hospitals, commercial laboratories, and public health agencies to assist with the research, diagnosis, treatment, and management of diseases.


All trademarks used or mentioned in this release are protected by law. Patents Pending – Use of this kit is covered by one or more of the following pending U.S. and International Patents: US 14/888,739, PCT/US2013/069172, EP 13853068.8